Urolithin A vs Methylene Blue
Urolithin A and methylene blue both come up in conversations about mitochondria, but they are fundamentally different things — one is a food-derived compound studied as a dietary supplement, the other is a century-old synthetic dye that is also an approved prescription drug. Here is an honest, mechanism-level comparison so you understand what each one actually is.
The quickest way to tell them apart
Urolithin A is a postbiotic — a compound your gut bacteria make when you eat foods rich in ellagitannins, such as pomegranates, walnuts, and certain berries. It is studied primarily for its effect on mitophagy, the cellular process that clears out damaged mitochondria so healthier ones can take their place. It is sold as a dietary supplement and is not a drug.
Methylene blue (methylthioninium chloride) is a synthetic compound first made in the 1870s. It is an FDA-approved prescription medication for a specific blood condition called methemoglobinemia, and it has a long history in medicine and laboratory staining. In recent years it has been marketed to consumers for "mitochondrial" and cognitive purposes, but that consumer use is not an approved indication, and methylene blue carries genuine drug-level safety considerations that a food-derived supplement does not. These two belong in different categories, and that difference matters more than any head-to-head "which is better" framing.
How each one works at the mitochondrion
Urolithin A: supporting quality control
Urolithin A acts upstream of energy production, on mitochondrial maintenance. The foundational preclinical work by Ryu and colleagues (Nature Medicine, 2016) showed in roundworms and rodents that urolithin A induced mitophagy and improved markers of muscle function. The idea is that by helping the cell recycle worn-out mitochondria, you support the overall quality of the mitochondrial pool rather than forcing any single reaction to run faster. We label that mechanism work as preclinical because it comes from animal and cell models; it points to how urolithin A behaves, not to a certain result in humans.
Methylene blue: cycling electrons in the chain
Methylene blue works very differently. At low concentrations it can act as an alternative electron carrier — a small molecule that picks up electrons and hands them off within the electron transport chain, in effect offering a side route around certain steps. It cycles between oxidized and reduced forms, which is why it is sometimes described as a redox agent. Importantly, this behavior is dose-dependent and hormetic: the low-dose electron-cycling effect can flip at higher concentrations, where methylene blue can instead act as a pro-oxidant and generate the very reactive oxygen species it is supposed to help with. Much of the mitochondrial and cognitive research on methylene blue is preclinical or early-stage, and the therapeutic window is narrow.
The human evidence, side by side
For urolithin A, several randomized controlled human trials exist. Andreux and colleagues (Nature Metabolism, 2019) established safety and tolerability up to 1,000 mg/day and found a mitochondrial gene-expression signature in older adults. Singh and colleagues (Cell Reports Medicine, 2022) and Liu/D'Amico and colleagues (JAMA Network Open, 2022) reported improvements in muscle endurance and performance over roughly four months. A 2025 randomized placebo-controlled study (Nature Aging) reported support for immune-cell mitochondrial health in midlife adults. These are early-stage and focused heavily on muscle and cellular markers, but they are genuine human data.
For methylene blue, the strongest and most established human evidence is for its approved medical use in methemoglobinemia and as a surgical dye — not for everyday cognitive enhancement or anti-aging. The consumer-facing claims about memory and mitochondrial energy rest largely on preclinical studies and small, preliminary human work. That is a meaningful gap: one of these compounds has a modest but real base of modern randomized human supplement trials, and the other is mostly being extrapolated from lab models and an unrelated approved indication.
Safety: the biggest practical difference
This is where the two genuinely diverge, and it is the part most worth taking seriously. Urolithin A has been well tolerated in human trials at doses up to 1,000 mg per day, with a safety profile consistent with its origin as a food-derived postbiotic.
Methylene blue is a drug with drug-level risks. It has monoamine oxidase inhibitor (MAOI) activity, which means it can interact dangerously with serotonergic medications — including many common antidepressants — and the FDA has specifically warned that this combination can cause serotonin syndrome, a potentially life-threatening reaction. It can also cause problems in people with G6PD deficiency, interacts with other medications, and turns urine and other fluids blue. It is not something to self-experiment with casually, and anyone considering it should do so only under medical supervision. This is not a knock on methylene blue in its legitimate medical role; it is simply an honest statement that a prescription drug and a dietary supplement are not interchangeable.
Can you compare them fairly at all?
Only loosely, because they are trying to do different things. Urolithin A is about mitochondrial housekeeping — clearing and replacing damaged units over weeks and months, with effects studied mainly in muscle and cellular markers. Methylene blue, in the mitochondrial context, is about electron handling in the moment, with a narrow dose window and a drug-interaction profile. If what you want is a well-tolerated, food-derived supplement with modern human trials behind it, urolithin A is the one that fits that description. If you are drawn to methylene blue, treat it as the drug it is and involve a physician.
If you are weighing urolithin A against other popular compounds, our comparisons of urolithin A vs NMN and urolithin A vs CoQ10 cover other options in the mitochondrial and longevity space, the urolithin A guide pulls the full picture together, and our best urolithin A gummies roundup compares formats.
The honest bottom line
These two are not rivals so much as residents of different worlds. Urolithin A is a dietary supplement studied for mitophagy, with a handful of human trials and a clean tolerability record. Methylene blue is an approved prescription drug being repurposed by consumers on the strength of mostly preclinical data, with real interaction and dosing risks. Neither is a cure for anything. For most people interested in supporting cellular energy through a supplement, urolithin A is the more straightforward, better-characterized choice — and methylene blue is a conversation to have with a doctor, not a bottle to grab off a shelf.
Is methylene blue a supplement or a drug?
Methylene blue is an FDA-approved prescription drug for a blood condition called methemoglobinemia and is also used as a medical and laboratory dye. Its use for cognitive or anti-aging purposes is not an approved indication. Urolithin A, by contrast, is a food-derived compound sold as a dietary supplement. They are in different regulatory categories.
Can I take urolithin A and methylene blue together?
This is a question for a physician, not a website, because methylene blue has MAOI activity and significant drug-interaction risks, including the potential for serotonin syndrome with certain medications. We don't recommend self-combining a prescription-category compound with anything. If you take any medications, talk to your doctor before considering methylene blue at all.
Which one has more human research behind it for everyday use?
For supplement-style use, urolithin A has several modern randomized controlled trials in humans — though they are early-stage and focused mainly on muscle. Methylene blue's strongest human evidence is for its approved medical uses; its consumer cognitive and mitochondrial claims rest largely on preclinical and preliminary data.
Do they work by the same mechanism?
No. Urolithin A is studied for inducing mitophagy — the recycling of damaged mitochondria — which is an upstream, quality-control effect seen mainly in preclinical models and some human markers. Methylene blue acts as an alternative electron carrier within the electron transport chain, a dose-dependent redox effect that can reverse at higher concentrations.
Is methylene blue safe to self-experiment with?
We'd urge caution. It has a narrow dosing window, MAOI activity, interactions with common antidepressants, risks in people with G6PD deficiency, and the FDA has warned about serotonin syndrome. It is a drug and should be approached as one, under medical supervision — not a casual biohacking experiment.
Is urolithin A a cure or treatment for low energy?
No. Urolithin A is not intended to diagnose, treat, cure, or prevent any disease. It is studied as support for healthy mitochondrial function, and the most reliable foundations for cellular energy remain exercise, sleep, and diet.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This guide is educational and is not a substitute for advice from a qualified healthcare provider.
A clinically studied 1,000 mg dose of Urolithin A in one simple daily gummy — to support mitophagy, muscle strength, and cellular energy.
Shop SOMA Urolithin A Gummies →